Fate Therapeutics, Inc. (FATE)
- Previous Close
4.7800 - Open
4.7900 - Bid 4.5300 x 900
- Ask 4.5600 x 900
- Day's Range
4.4850 - 5.0200 - 52 Week Range
1.6300 - 8.8300 - Volume
3,992,798 - Avg. Volume
2,752,261 - Market Cap (intraday)
516.575M - Beta (5Y Monthly) 1.68
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6400 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.80
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
www.fatetherapeutics.comRecent News: FATE
Performance Overview: FATE
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FATE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FATE
Valuation Measures
Market Cap
544.91M
Enterprise Value
333.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.42
Price/Book (mrq)
1.48
Enterprise Value/Revenue
5.25
Enterprise Value/EBITDA
-1.94
Financial Highlights
Profitability and Income Statement
Profit Margin
-253.30%
Return on Assets (ttm)
-18.32%
Return on Equity (ttm)
-37.76%
Revenue (ttm)
63.53M
Net Income Avi to Common (ttm)
-160.93M
Diluted EPS (ttm)
-1.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
315.18M
Total Debt/Equity (mrq)
28.10%
Levered Free Cash Flow (ttm)
-74.25M
Research Analysis: FATE
Company Insights: FATE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: FATE
Daily – Vickers Top Buyers & Sellers for 01/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/14/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/13/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/13/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.